Donor-Derived iPS Cells Show Promise for Treating Eye Disease
Donor-Derived iPS Cells Show Promise for Treating Eye Disease
Age-related macular degeneration patients who received injections of retinal cells derived from donors’ induced pluripotent stem cells have maintained their level of eyesight for a year.
Donor-Derived iPS Cells Show Promise for Treating Eye Disease
Donor-Derived iPS Cells Show Promise for Treating Eye Disease

Age-related macular degeneration patients who received injections of retinal cells derived from donors’ induced pluripotent stem cells have maintained their level of eyesight for a year.

Age-related macular degeneration patients who received injections of retinal cells derived from donors’ induced pluripotent stem cells have maintained their level of eyesight for a year.

stem cell trials

Texas Stem Cell Law Opens Door for Controversial Treatments
Anna Azvolinsky | Mar 27, 2018
The Scientist looks at one such Houston-based purveyor that has been treating patients abroad for years with mesenchymal stem cells.
CIRM Ups Translational Velocity
Bob Grant | Dec 20, 2015
California’s stem cell agency unveiled a 5-year plan that includes starting 50 new clinical trials.
Hearts on Trial
Kerry Grens | May 1, 2015
As researchers conduct the most rigorous human trials of cardiac cell therapies yet attempted, a clear picture of whether these treatments actually work is imminent.
Heart Strings
The Scientist Staff | Apr 30, 2015
An animated primer on the harvesting, growth, and administration of cardiac cells to heart attack patients
Stem Cell Trial for Eye Disease Commences
Jef Akst | Sep 12, 2014
Researchers at the RIKEN Center for Developmental Biology will treat the first patient in its clinical trial testing an induced pluripotent stem cell-based treatment for age-related macular degeneration.
Done with Immunosuppressants
Jef Akst | Jul 3, 2014
Adult sickle-cell patients have safely stopped taking their immunosuppressant medication thanks to a new type of blood stem-cell transplant.
Geron hESC Trial to Resume?
Jef Akst | May 27, 2014
Nearly three years after Geron shuttered its stem cell program, BioTime receives funding to relaunch a Phase 1 trial for spinal cord injury.
More Evidence of Stem Cell Errors
Kerry Grens | Feb 25, 2014
A committee at the University of Düsseldorf finds misconduct in cardiologist Bodo-Eckehard Strauer’s work.  
Stem-Cell Clinic Moves to Mexico
Dan Cossins | Feb 1, 2013
A company offering experimental stem-cell treatments will carry out its procedures in Mexico after the FDA warned that it would need approval to operate in the U.S.
 
Opinion: Regenerating Safely
Dan Orlando | Jan 21, 2013
Patient safety is paramount in regulating new stem cell treatments.
BioTime Seeks Geron Stem Cell Assets
Vicki Brower | Nov 13, 2012
Two former Geron CEOs make a bid for the company’s defunct human embryonic stem cell business.
Stem Cells Myelinate Human Brain
Sabrina Richards | Oct 10, 2012
In a Phase I trial, researchers show that neural stem cells transplanted into humans can differentiate and begin producing myelin.
An Eye for Stem Cells
Hannah Waters | Dec 1, 2011
Japanese researchers are launching an iPS cell trial for an untreatable eye disease, challenging ongoing embryonic stem cell trials.